Coding Manual:
Hematopoietic Coding Manual (PDF)
Abstractor Notes
(This code is effective for cases diagnosed 2010 and later. For cases diagnosed prior to 2010 see code 9801/3.)
Mixed-phenotype acute leukemia (MPAL), B/myeloid is part of the Acute leukemias of mixed or ambiguous lineage table in the WHO 5th edition of Hematolymphoid Tumors. (See Appendix B in the Hematopoietic Manual, Table B9)
Bone marrow and peripheral blood are always involved.
Mixed-phenotype acute leukemia (MPAL), B/myeloid is part of the Acute leukemias of mixed or ambiguous lineage table in the WHO 5th edition of Hematolymphoid Tumors. (See Appendix B in the Hematopoietic Manual, Table B9)
Bone marrow and peripheral blood are always involved.
Diagnostic Confirmation
This histology can be determined by positive histology (including peripheral blood) with or without genetics and/or immunophenotyping. Review the Definitive Diagnostic Methods, Immunophenotyping and Genetics Data sections below, and the instructions in the Hematopoietic Manual for further guidance on assigning Diagnostic confirmation.
Module Rule
None
Alternate Names
None
Definition
Definitive Diagnostic Methods
Cytogenetics
Genetic testing
Histologic confirmation
Immunophenotyping
Immunohistochemistry
Genetics Data
Immunophenotyping
CD19+ (expression/positive)
CD20+ (expression/positive)
CD22+ (expression/positive)
cCD79a+ (expression/positive)
PAX5
Treatments
Chemotherapy
Transformations to
There are no known transformations
Transformations from
There are no known transformations
Same Primaries
Corresponding ICD-10 Codes (Cause of Death codes only)
C95.0 Acute leukemia of unspecified cell type
Corresponding ICD-10-CM Codes (U.S. only)
C95.0 Acute leukemia of unspecified cell type (effective October 01, 2015 - September 30, 2024)
C95.00 Acute leukemia of unspecified cell type not having achieved remission (effective October 01, 2024)
C95.01 Acute leukemia of unspecified cell type, in remission (effective October 01, 2024)
C95.02 Acute leukemia of unspecified cell type, in relapse (effective October 01, 2024)
Signs and Symptoms
Diagnostic Exams
Bone marrow aspiration and biopsy
Flow cytometry
Cytogenetic analysis
Immunophenotyping
Lumbar puncture
Molecular testing
Peripheral blood smear
Physical exam and history
Progression and Transformation
None
Epidemiology and Mortality
Sources
WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. Lyon (France): International Agency for Research on Cancer; 2024. (WHO classification of tumours series, 5th ed.; vol. 11). https://publications.iarc.who.int/637.
Section: Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions
Pages: Part A: 212-213
Section: Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions
Pages: Part A: 212-213
International Classification of Diseases for Oncology, 3rd edition (including revisions). Geneva: World Health Organization, 2001, 2011, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
Home